High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection

International Journal of Cancer

Volumn 101, Issue 6, 2002, Pages 519-525

  Liang, Jin Tung ^a   Huang, Kuo Chin ^a   Lai, Hong Shiee ^a   Lee, Po Huang ^a   Cheng, Yung Ming ^a   Hsu, Hey Chi ^a   Cheng, Ann Lii ^a   Hsu, Chih Hung ^a   Yeh, Kun Huei ^a   Wang, Shih Ming ^a   Tang, Chi ^a   Chang, King Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Colorectal cancer; High dose 5 fluorouracil plus leucovorin chemotherapy; Microsatellite instability

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOMAL LOCALIZATION; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG MEGADOSE; FATIGUE; FEMALE; FEVER; GENE SILENCING; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; NEUROTOXICITY; PALLIATIVE THERAPY; PREDICTION; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; COLON; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 0037145305     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10643     Document Type: Article

References (54)

1. Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Wu MS, Wang SM, Lin JT, Cheng AL. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology 1999;57:149-56.
2. Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Chien CT, Wang SM. Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection. Hepatogastroenterology 1999;46:883-90.
3. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
4. Lothe RA, Peltomäki P, Meling GI, Aaltonen LA, Nyström-Lahti M, Pylkkänen L, Heimdal K, Andersen TI, Møller P, Rognum TO, Fosså SD, Haldorsen T, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849-52.
5. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC, Wyllie AH. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996;12:2641-9.
6. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O'Connell MJ, Witzig TE, Farr GH Jr, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295-303.
7. Gafa R, Maestri I, Matteuzzi M, Santini A, Ferretti S, Cavazzini L, Lanza G. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 2000;89:2025-37.
8. Ko JM, Cheung MH, Kwan MW, Wong CM, Lau KW, Tang CM, Lung ML. Genomic instability and alterations in APC, MCC and DCC in Hong Kong patients with colorectal carcinoma. Int J Cancer 1999; 84:404-9.
9. Salahshor S, Kressner U, Fischer H, Lindmark G, Glimelius B, Påhlman L, Lindblom A. Microsatellite instability in sporadic colorectal carcinoma is not an independent prognostic factor. Br J Cancer 1999;81:190-3.
10. Feeley KM, Fullard JF, Heneghan MA, Smith T, Maher M, Murphy RP, O'Gorman TA. Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis. J Pathol 1999;188:14-7.
11. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
12. Hermanek P, Sobin LH, Wittekind C. How to improve the present TNM staging system. Cancer 1999;86:2189-91.
13. Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF, Drucker W, Kirsch I, Hamilton SR. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 1998;227:51-6.
14. Gryfe R, Kim H, Hsieh ETK, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancers. N Engl J Med 2000;342:69-77.
15. Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000;119:921-8.
16. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumor site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000;355:1745-50.
17. Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, Iacopetta B. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 2000;58:52-9.
18. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B. p53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001;7:1343-9.
19. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB 3rd, Hamilton SR. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344: 1196-206.
20. Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL, Howell SB. Resistance to cytotoxin drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997;3:1763-7.
21. Carethers JM, Chauhan DJ, Fink D, Nebel S, Bresalier RS, Howell SB, Boland CR. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117:123-31.
22. Hermanek P. Prognostic factor research in oncology. J Clin Epidemiol 1999;52:371-4.
23. McLeod RS. Issues in surgical randomized controlled trials. World J Surg 1999;23:1210-4.
24. Nicoll ID, Dunlop MG. Molecular markers for colorectal cancer. J Natl Cancer Inst 1999;91:1267-9.
25. Offit K. Genetic prognostic markers for colorectal cancer. N Engl J Med 2000;342:124-5.
26. Ardalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9:625-30.
27. Yeh KH, Cheng AL. An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leucovorin. J Clin Oncol 1994;12:875-6.
28. Yeh KH, Cheng AL, Lin MT, Hong RL, Hsu CH, Lin JF, Chang KJ, Lee PH, Chen YC. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers. Anticancer Res 1997;17: 3867-72.
29. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
30. Liang JT, Cheng YM, Chang KJ, Chien CT, Hsu HC. Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes' B2 rectal cancer after curative resection. Hepatogastroenterology 1999;46:830-7.
31. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
32. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999;91:1281-7.
33. Liang JT, Huang KC, Cheng YM, Hsu HC, Cheng AL, Hsu CH, Yeh KH, Wang SM, Chang KJ. p53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 2002;97:451-7.
34. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV. Quantitation of intratumoral thymidylate synthetase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15: 3223-9.
35. Harris BE, Song R, Soong S, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
36. Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994;54:5059-63.
37. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90.
38. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-4.
39. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B. Inactivation of the type II TGF-β receptor colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
40. Calin GA, Gafa R, Tibiletti MG, Herlea V, Becheanu G, Cavazzini L, Barbanti-Brodano G, Nenci I, Negrini M, Lanza G. Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinicopathological parameters: a study of the TGFβRII, BAX, HMSH3, HMSH6, IGFIIR and BLM genes. Int J Cancer 2000; 89:230-5.
41. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-6.
42. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human cell lines. Cancer Res 1997;57: 808-11.
43. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, et al. Incidence and functional consequences of hMLHI promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870-5.
44. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Martinez Monge R, Salgado E, Angeletti S, Brugarolas A. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthetase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001;19:1779-86.
45. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
46. Claij N, te Riele H. Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Exp Cell Res 1999;246:1-10.
47. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6.
48. Gariboldi M, Gupta M, Boland CR, Pommier Y. Increased sensitivity to camptothecin in human colon carcinoma cell lines with mismatch repair deficiency [abstract]. Proc Am Assoc Cancer Res 1996;37:431.
49. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute Anticancer Screen. Cancer Res 1995;55:2116-21.
50. Berry SE, Garces C, Hwang HS, Kunugi K, Meyers M, Davis TW, Boothman DA, Kinsella TJ. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells. Cancer Res 1999;59:1840-5.
51. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB. The role of mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
52. Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, Ali-Osman F, Dolan E, Colvin OM, Houghton P, Germain G, Drummond JT, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997;57:2933-6.
53. Woynarowski M, Chapman WG, Napier G, Raymond E. Oxaliplatin (OxPt) effects on naked and intracellular DNA [abstract]. Proc Am Assoc Cancer Res 1997;38:311.
54. Pepponi R, Graziani G, Falcinelli S, Vernole P, Levati L, Lacal PM, Pagani E, Bonmassar E, Jiricny J, D'Atri S. hMSH3 overexpression and cellular response to cytotoxic anticancer agents. Carcinogenesis 2001;22:1131-7.